MYCN/c-MYC-induced microRNAs repress coding gene networks associated with poor outcome in MYCN/c-MYC-activated tumors

Oncogene

Volumn 29, Issue 9, 2010, Pages 1394-1404

  Mestdagh, P ^a   Fredlund, E ^a   Pattyn, F ^a   Schulte, J H ^b   Muth, D ^c   Vermeulen, J ^a   Kumps, C ^a   Schlierf, S ^b   De Preter, K ^a   Van Roy, N ^a   Noguera, R ^d   Laureys, G ^a   Schramm, A ^b   Eggert, A ^b   Westermann, F ^c   Speleman, F ^a   Vandesompele, J ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b UNIVERSITY HOSPITAL ESSEN   (Germany)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^d UNIVERSITY OF VALENCIA   (Spain)

Author keywords

C MYC; MicroRNA; MYCN; Neuroblastoma

Indexed keywords

MESSENGER RNA; MICRORNA;

ARTICLE; CANCER CELL CULTURE; CHROMATIN IMMUNOPRECIPITATION; GENE FUNCTION; GENE REPRESSION; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; NEUROBLASTOMA; ONCOGENE C MYC; ONCOGENE MYC; PRIORITY JOURNAL; PROTEIN BINDING;

CELL LINE, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE REGULATORY NETWORKS; GENE SILENCING; GENES, MYC; HUMANS; MICRORNAS; NEUROBLASTOMA; NUCLEAR PROTEINS; ONCOGENE PROTEINS; PROMOTER REGIONS, GENETIC; RNA, SMALL INTERFERING; TRANSCRIPTION FACTORS; TREATMENT OUTCOME;

EID: 77949267058     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2009.429     Document Type: Article

References (45)

1. Adhikary S, Eilers M. (2005). Transcriptional regulation and transformation by Myc proteins. Nat Rev Mol Cell Biol 6: 635-645.
2. Baek D, Villen J, Shin C, Camargo FD, Gygi SP, Bartel DP. (2008). The impact of microRNAs on protein output. Nature 455: 64-71.
3. Bartel DP. (2009). MicroRNAs: target recognition and regulatory functions. Cell 136: 215-233.
4. Bild AH, Yao G, Chang JT, Wang Q, Potti A, Chasse D, et al. (2006). Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 439: 353-357.
5. Cappellen D, Schlange T, Bauer M, Maurer F, Hynes NE. (2007). Novel c-MYC target genes mediate differential effects on cell proliferation and migration. EMBO Rep 8: 70-76.
6. Chang CC, Liu YC, Cleveland RP, Perkins SL. (2000). Expression of c-Myc and p53 correlates with clinical outcome in diffuse large B-cell lymphomas. Am J Clin Pathol 113: 512-518.
7. Chang TC, Yu D, Lee YS, Wentzel EA, Arking DE, West KM, et al. (2008). Widespread microRNA repression by Myc contributes to tumorigenesis. Nat Genet 40: 43-50.
8. Chen Y, Stallings RL. (2007). Differential patterns of microRNA expression in neuroblastoma are correlated with prognosis, differentiation, and apoptosis. Cancer Res 67: 976-983.
9. Dews M, Homayouni A, Yu D, Murphy D, Sevignani C, Wentzel E, et al. (2006). Augmentation of tumor angiogenesis by a Myc-activated microRNA cluster. Nat Genet 38: 1060-1065.
10. Fontana L, Fiori ME, Albini S, Cifaldi L, Giovinazzi S, Forloni M, et al. (2008). Antagomir-17-5p abolishes the growth of therapy-resistant neuroblastoma through p21 and BIM. PLoS One 3: e2236.
11. Fredlund E, Ringner M, Maris JM, Pahlman S. (2008). High Myc pathway activity and low stage of neuronal differentiation associate with poor outcome in neuroblastoma. Proc Natl Acad Sci USA 105: 14094-14099.
12. Gartel AL. (2006). A new mode of transcriptional repression by c-myc: methylation. Oncogene 25: 1989-1990.
13. Jiang M, Zhu K, Grenet J, Lahti JM. (2008). Retinoic acid induces caspase-8 transcription via phospho-CREB and increases apoptotic responses to death stimuli in neuroblastoma cells. Biochim Biophys Acta 1783: 1055-1067.
14. Kleine-Kohlbrecher D, Adhikary S, Eilers M. (2006). Mechanisms of transcriptional repression by Myc. Curr Top Microbiol Immunol 302: 51-62.
15. Kramer MH, Hermans J, Wijburg E, Philippo K, Geelen E, van Krieken JH, et al. (1998). Clinical relevance of BCL2, BCL6, and MYC rearrangements in diffuse large B-cell lymphoma. Blood 92: 3152-3162.
16. Landais S, Landry S, Legault P, Rassart E. (2007). Oncogenic potential of the miR-106-363 cluster and its implication in human T-cell leukemia. Cancer Res 67: 5699-5707.
17. Lee Y, Samaco RC, Gatchel JR, Thaller C, Orr HT, Zoghbi HY. (2008). miR-19, miR-101 and miR-130 co-regulate ATXN1 levels to potentially modulate SCA1 pathogenesis. Nat Neurosci 11: 1137-1139.
18. Lenz G, Wright G, Dave SS, Xiao W, Powell J, Zhao H, et al. (2008). Stromal gene signatures in large-B-cell lymphomas. N Engl J Med 359: 2313-2323.
19. Liu Y, Ringner M. (2007). Revealing signaling pathway deregulation by using gene expression signatures and regulatory motif analysis. Genome Biol 8: R77.
20. Malynn BA, de Alboran IM, O'Hagan RC, Bronson R, Davidson L, DePinho RA, et al. (2000). N-myc can functionally replace c-myc in murine development, cellular growth, and differentiation. Genes Dev 14: 1390-1399.
21. Mestdagh P, Feys T, Bernard N, Guenther S, Chen C, Speleman F, et al. (2008). High-throughput stem-loop RT-qPCR miRNA expression profiling using minute amounts of input RNA. Nucleic Acids Res 36: e143.
22. Mestdagh P, Van Vlierberghe P, De Weer A, Muth D, Westermann F, Speleman F, et al. (2009). A novel and universal method for microRNA RT-qPCR data normalization. Genome Biol 10: R64.
23. Northcott PA, Fernandez LA, Hagan JP, Ellison DW, Grajkowska W, Gillespie Y, et al. (2009). The miR-17/92 polycistron is up-regulated in sonic hedgehog-driven medulloblastomas and induced by N-myc in sonic hedgehog-treated cerebellar neural precursors. Cancer Res 69: 3249-3255.
24. O'Donnell KA, Wentzel EA, Zeller KI, Dang CV, Mendell JT. (2005). c-Myc-regulated microRNAs modulate E2F1 expression. Nature 435: 839-843.
25. Oberthuer A, Berthold F, Warnat P, Hero B, Kahlert Y, Spitz R, et al. (2006). Customized oligonucleotide microarray gene expression-based classification of neuroblastoma patients outperforms current clinical risk stratification. J Clin Oncol 24: 5070-5078.
26. Park DS, Razani B, Lasorella A, Schreiber-Agus N, Pestell RG, Iavarone A, et al. (2001). Evidence that Myc isoforms transcription-ally repress caveolin-1 gene expression via an INR-dependent mechanism. Biochemistry 40: 3354-3362.
27. Peterson S, Bogenmann E. (2004). The RET and TRKA pathways collaborate to regulate neuroblastoma differentiation. Oncogene 23: 213-225.
28. Saito-Ohara F, Imoto I, Inoue J, Hosoi H, Nakagawara A, Sugimoto T, et al. (2003). PPM1D is a potential target for 17q gain in neuroblastoma. Cancer Res 63: 1876-1883.
29. Sampson VB, Rong NH, Han J, Yang Q, Aris V, Soteropoulos P, et al. (2007). MicroRNA let-7a down-regulates MYC and reverts MYC-induced growth in Burkitt lymphoma cells. Cancer Res 67: 9762-9770.
30. Sander S, Bullinger L, Klapproth K, Fiedler K, Kestler HA, Barth TF, et al. (2008). MYC stimulates EZH2 expression by repression of its negative regulator miR-26a. Blood 112: 4202-4212.
31. Schulte JH, Horn S, Otto T, Samans B, Heukamp LC, Eilers UC, et al. (2008). MYCN regulates oncogenic microRNAs in neuroblastoma. Int J Cancer 122: 699-704.
32. Seeger RC, Brodeur GM, Sather H, Dalton A, Siegel SE, Wong KY, et al. (1985). Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med 313: 1111-1116.
33. Selbach M, Schwanhausser B, Thierfelder N, Fang Z, Khanin R, Rajewsky N. (2008). Widespread changes in protein synthesis induced by microRNAs. Nature 455: 58-63.
34. Stupack DG, Teitz T, Potter MD, Mikolon D, Houghton PJ, Kidd VJ, et al. (2006). Potentiation of neuroblastoma metastasis by loss of caspase-8. Nature 439: 95-99.
35. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. (2005). Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 102: 15545-15550.
36. Sun Y, Wu J, Wu SH, Thakur A, Bollig A, Huang Y, et al. (2008). Expression profile of microRNAs in c-Myc induced mouse mammary tumors. Breast Cancer Res Treat 118: 185-196.
37. Tan LP, Seinen E, Duns G, de Jong D, Sibon OC, Poppema S, et al. (2009). A high throughput experimental approach to identify miRNA targets in human cells. Nucleic Acids Res 37: e137.
38. Van Roy N, Laureys G, Cheng NC, Willem P, Opdenakker G, Versteeg R, et al. (1994). 1;17 translocations and other chromosome 17 rearrangements in human primary neuroblastoma tumors and cell lines. Genes Chromosomes Cancer 10: 103-114.
39. Van Roy N, Vandesompele J, Menten B, Nilsson H, De Smet E, Rocchi M, et al. (2006). Translocation-excision-deletion-amplifica-tion mechanism leading to nonsyntenic coamplification of MYC and ATBF1. Genes Chromosomes Cancer 45: 107-117.
40. Vandesompele J, Edsjo A, De Preter K, Axelson H, Speleman F, Pahlman S. (2003). ID2 expression in neuroblastoma does not correlate to MYCN levels and lacks prognostic value. Oncogene 22: 456-460.
41. Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, et al. (2006). A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA 103: 2257-2261.
42. Wang Q, Diskin S, Rappaport E, Attiyeh E, Mosse Y, Shue D, et al. (2006). Integrative genomics identifies distinct molecular classes of neuroblastoma and shows that multiple genes are targeted by regional alterations in DNA copy number. Cancer Res 66: 6050-6062.
43. Watters JW, Roberts CJ. (2006). Developing gene expression signatures of pathway deregulation in tumors. Mol Cancer Ther 5: 2444-2449.
44. Westermann F, Muth D, Benner A, Bauer T, Henrich KO, Oberthuer A, et al. (2008). Distinct transcriptional MYCN/c-MYC activities are associated with spontaneous regression or malignant progression in neuroblastomas. Genome Biol 9: R150.
45. Zeller KI, Jegga AG, Aronow BJ, O'Donnell KA, Dang CV. (2003). An integrated database of genes responsive to the Myc oncogenic transcription factor: identification of direct genomic targets. Genome Biol 4: R69.